熱門資訊> 正文
SK BiopharmPharmaceuticals以7.95亿美元收购癫痫药物opakalim，Biohaven股价上涨13%
2026-08-26 19:00
- Biohaven (BHVN) stock price surged about 13% on Wednesday pre-market trade as it entered a global licensing and collaboration agreement with SK Biopharmaceuticals for its Kv7 ion channel platform, led by epilepsy candidate opakalim (BHV-7000).
- The deal could provide Biohaven (BHVN) with up to $795M in upfront and milestone payments. Breaking down $400M comprises near-term cash consideration, with $350M at closing and $50M in 2027.
- The company is also eligible for $150M in development and regulatory milestones, as well as tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim and mid-single-digit royalties on sales outside the U.S.
- Opakalim is a selective Kv7.2/7.3 potassium channel activator in Phase 2/3 development for focal epilepsy. Topline results from its RISE3 trial are expected in H2 2026.
More on Biohaven
- Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk
- Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations
- These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations
- Seeking Alpha’s Quant Rating on Biohaven
- Historical earnings data for Biohaven
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
